EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Meeting Patient Expectations of Topical Psoriasis Treatment: Evidence Supporting the Use of Fixed-Combination Halobetasol/Tazarotene Lotion

James Del Rosso, George Han, April Armstrong, G Michael Lewitt, Abby Jacobson

Journal of Drugs in Dermatology · 2023

DOI: 10.36849/jdd.7367 ↗

At a glance

Übersichtsarbeit in Journal of Drugs in Dermatology, 2023. Written by James Del Rosso and 4 co-authors. Major MEDLINE topics: Dermatologic Agents, Psoriasis, Nicotinic Acids.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Discordance between patient and clinician treatment goals and expectations can present a challenge to implementation of effective therapeutic plans. Because topical treatments are commonly used for plaque psoriasis, both as monotherapy and adjuncts to other treatment modalities, providers need to understand the concerns of patients with psoriasis regarding use of topical products. Psoriasis is a complex and chronic disease with treatment needs that may change over time, influencing patient treatment goals and expectations of efficacy. When these expectations are not met and patient concerns are unaddressed, dissatisfaction may lead to nonadherence, which in turn can prevent patients from achieving relief from the signs and symptoms of psoriasis that affect their quality of life. Here, we detail how current topical treatments meet patient expectations and needs, with particular attention given to combination regimens using corticosteroids. This review shows that once-daily application of halobetasol propionate (0.01%) and tazarotene (0.045%) lotion (HP/TAZ) not only has a rapid onset of treatment effect and proven efficacy, but also has a remittive effect. In addition, HP/TAZ has a favorable safety profile, with low rates of irritation and local skin reactions in clinical studies. The dual mechanisms of action related to 2 active ingredients, once-daily use, and the favorable clinical findings suggest that HP/TAZ may address patient concerns and promote treatment adherence.J Drugs Dermatol. 2023;22(2):132-138. doi:10.36849/JDD.7367.

Subjects

MeSH terms (MEDLINE)

Dermatologic AgentsPsoriasisNicotinic AcidsHumansDrug CombinationsMotivationQuality of LifeTreatment OutcomeSeverity of Illness IndexSkin CreamClobetasolEmollientsEmulsionsRetinoids

Substances

Drug CombinationsDermatologic AgentsClobetasolNicotinic AcidsEmollientsEmulsionshalobetasoltazaroteneRetinoids

Cite

APA

Del Rosso, J., Han, G., Armstrong, A., Lewitt, G. M., & Jacobson, A. (2023). Meeting Patient Expectations of Topical Psoriasis Treatment: Evidence Supporting the Use of Fixed-Combination Halobetasol/Tazarotene Lotion. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.7367

Vancouver

Del Rosso J, Han G, Armstrong A, Lewitt GM, Jacobson A. Meeting Patient Expectations of Topical Psoriasis Treatment: Evidence Supporting the Use of Fixed-Combination Halobetasol/Tazarotene Lotion. Journal of Drugs in Dermatology. 2023. doi:10.36849/jdd.7367

BibTeX
@article{DelRosso2023,
  author = {Del Rosso, James and Han, George and Armstrong, April and Lewitt, G Michael and Jacobson, Abby},
  title = {Meeting Patient Expectations of Topical Psoriasis Treatment: Evidence Supporting the Use of Fixed-Combination Halobetasol/Tazarotene Lotion},
  journal = {Journal of Drugs in Dermatology},
  year = {2023},
  doi = {10.36849/jdd.7367}
}
Start for free →